TCAI physicians participate in clinical trial for potential life-saving device for patients with heart rhythm disorders

Texas Cardiac Arrhythmia Institute at St. David's Medical Center  

PR87964

 

AUSTIN, Texas, Feb. 5, 2021 /PRNewswire=KYODO JBN/ --

 

Physicians with the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's

Medical Center [

https://c212.net/c/link/?t=0&l=en&o=3059247-1&h=2811931313&u=https%3A%2F%2Ftcainstitute.com%2F&a=Texas+Cardiac+Arrhythmia+Institute+(TCAI)+at+St.+David%27s+Medical+Center ]

are among the first in the world to participate in a clinical trial to

evaluate a new esophageal protection device designed to make ablation

procedures safer for patients with atrial fibrillation (A Fib), the most common

type of cardiac arrhythmia. Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C.,

cardiac electrophysiologist and executive medical director of TCAI, and Amin

Al-Ahmad, M.D., cardiac electrophysiologist at TCAI, recently participated in

the first-in-human trials in Europe.

 

Given the close proximity of the esophagus to the posterior wall of the left

atrium of the heart, thermal energy may enter into the esophagus during

ablation, causing an atrio-esophageal (AE) fistula, which is an abnormal

connection between the esophagus and atrium. It is among the most serious and

life-threatening complications from ablation. This device works by using

suction to pull the esophagus away using negative pressure during ablation

procedures.

 

"While esophageal injury is uncommon during ablation, perforation of the

esophagus can lead to sepsis, which is often fatal," Dr. Natale said. "This new

device may allow us to better protect the esophagus during ablation, further

reducing the risk of complication to ensure best possible outcomes for our

patients."

 

TCAI physicians tested the esophageal protection device on approximately 10

patients in Europe, with plans to make it available to TCAI patients upon FDA

approval. This technology could be available in the United States in two to

three years.

 

Media Contact:

Stacy Slayden

Elizabeth Christian Public Relations

SSlayden@EChristianPR.com

254.592.2767 cell

 

 

SOURCE:  Texas Cardiac Arrhythmia Institute at St. David's Medical Center  

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中